Dateline City:
BERKELEY, Calif., and KENILWORTH, N.J.
Study will Evaluate Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab),
in Combination with Plexxikons PLX3397
BERKELEY, Calif., and KENILWORTH, N.J. May 7, 2015 Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikons investigational CSF-1R inhibitor, and KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression.
Language:
English
read more